Presbyopia - Pipeline Insight, 2025

This “Presbyopia - Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Presbyopia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Presbyopia: Understanding

Presbyopia: Overview

Presbyopia is an age-related loss of lens accommodation that results in an inability to focus at near distances. It is the most common physiological change occurring in the adult eye and is thought to cause universal near vision. People who become presbyopia may complain of headaches and eye strain, and hold objects progressively further away from their eyes in order to be able to focus on them. The most common remedy is the prescription of a pair of reading spectacles. The prevalence of presbyopia in low- and middle-income countries is not well known, as most studies of refractive error in these countries have been limited to distance vision. There are various explanations about the pathophysiology of presbyopia. Among all the concepts, increased stiffness of the crystalline lens is the most popular and widely accepted. Presbyopia is a physiological condition wherein there is a progressive functional decline in the accommodative capacity of the crystalline lens. Clinically, it manifests as progressive difficulty in reading at the usual reading distance. Patients around 40 years of age present with complaints of difficulty in reading finger prints at usual reading distance. Typically, patients report improvement in near visual acuity if the reading distance is increased slightly beyond the usual reading distance. At the outset of symptoms, patients often complain of headaches. Asthenopic symptoms appear relatively earlier in patients with longer screen time exposure due to latent accommodative dysfunction.

Other symptoms include delayed focusing of near and distance, squinting, drowsiness during near work, and need for bright light for reading. Workers involved actively in sewing businesses find difficulty passing the thread through the needle.

The most significant indicator of the severity of presbyopia is the required near add power. Determining the near add power required by an individual is generally done by first establishing a tentative addition and visual needs, and most common working distance to establish a final adjustment. The most common remedy is the prescription of a pair of reading spectacles. Other treatment options include contact lenses, topical pilocarpine eyedrops, and corneal inlay surgery. However, there is currently no major pharmacologic therapy to address the unmet needs of presbyopia patients. Efforts to improve lens malleability offer an encouraging alternative to established methods of correcting presbyopia.

“Presbyopia - Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Presbyopia pipeline landscape is provided which includes the disease overview and Presbyopia treatment guidelines. The assessment part of the report embraces, in depth Presbyopia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Presbyopia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Presbyopia R&D. The therapies under development are focused on novel approaches to treat/improve Presbyopia.

Presbyopia Emerging Drugs Chapters

This segment of the Presbyopia report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Presbyopia Emerging Drugs

LNZ100: Lenz Therapeutics

LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine, a selective muscarinic receptor agonist. It works by constricting the pupil, creating a pinhole effect that improves near vision. Unlike other pupil-constricting agents, aceclidine has a unique mechanism of action that decouples the miotic effect from the stimulation of the ciliary muscle, reducing the risk of myopic shift and accompanying brow ache. This allows LNZ100 to provide a broad patient population with a long-lasting and efficient treatment for presbyopia, a condition characterized by the gradual hardening of the lens and decline in near vision with age. US Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for LNZ100 for the treatment of presbyopia. Currently, the drug is in registration stage of its clinical trial for the treatment of presbyopia.

GLK-302: Glaukos Corporation

Glaukos Corporation is developing GLK-302, a sterile ophthalmic topical cream containing the active ingredient pilocarpine, for the treatment of presbyopia. GLK-302 is designed to be applied to the eyelid, allowing the pilocarpine to be delivered through the dermis to the eye. The mechanism of action involves pilocarpine, a muscarinic acetylcholine receptor agonist, which acts on the M3 and M1 receptors in the eye to cause pupillary constriction and increase the depth of focus, thereby improving near visual acuity in presbyopic patients without significantly deteriorating distance vision. Currently, the drug is in Phase II stage of its clinical trial for the treatment of presbyopia.

Presbyopia: Therapeutic Assessment

This segment of the report provides insights about the different Presbyopia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Presbyopia

There are approx. 10+ key companies which are developing the therapies for Presbyopia. The companies which have their Presbyopia drug candidates in the most advanced stage, i.e. Phase III include Lenz Therapeutics.

Phases

The report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Presbyopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Presbyopia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Presbyopia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Presbyopia drugs.

Presbyopia Report Insights

• Presbyopia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Presbyopia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Presbyopia drugs?
• How many Presbyopia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Presbyopia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Presbyopia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Presbyopia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Visus Therapeutics
• Glaukos Corporation
• Cellix Bio
• Orasis Pharmaceuticals
• Cellix Bio

Key Products

• VTI-001
• GLK-302
• CLX-OPH-162
• CSF-1
• CLX-OPH-162

This product will be delivered within 2 business days.